Literature DB >> 22904263

Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups.

Kenneth M Kaufman1, Jian Zhao, Jennifer A Kelly, Travis Hughes, Adam Adler, Elena Sanchez, Joshua O Ojwang, Carl D Langefeld, Julie T Ziegler, Adrienne H Williams, Mary E Comeau, Miranda C Marion, Stuart B Glenn, Rita M Cantor, Jennifer M Grossman, Bevra H Hahn, Yeong Wook Song, Chack-Yung Yu, Judith A James, Joel M Guthridge, Elizabeth E Brown, Graciela S Alarcón, Robert P Kimberly, Jeffrey C Edberg, Rosalind Ramsey-Goldman, Michelle A Petri, John D Reveille, Luis M Vilá, Juan-Manuel Anaya, Susan A Boackle, Anne M Stevens, Barry I Freedman, Lindsey A Criswell, Bernardo A Pons Estel, Joo-Hyun Lee, Ji-Seon Lee, Deh-Ming Chang, R Hal A Scofield, Gary S Gilkeson, Joan T Merrill, Timothy B Niewold, Timothy James Vyse, Sang-Cheol Bae, Marta E Alarcón-Riquelme, Chaim O Jacob, Kathy Moser Sivils, Patrick M Gaffney, John B Harley, Amr H Sawalha, Betty P Tsao.   

Abstract

OBJECTIVES: The Xq28 region containing IRAK1 and MECP2 has been identified as a risk locus for systemic lupus erythematosus (SLE) in previous genetic association studies. However, due to the strong linkage disequilibrium between IRAK1 and MECP2, it remains unclear which gene is affected by the underlying causal variant(s) conferring risk of SLE.
METHODS: We fine-mapped ≥136 SNPs in a ∼227 kb region on Xq28, containing IRAK1, MECP2 and seven adjacent genes (L1CAM, AVPR2, ARHGAP4, NAA10, RENBP, HCFC1 and TMEM187), for association with SLE in 15 783 case-control subjects derived from four different ancestral groups.
RESULTS: Multiple SNPs showed strong association with SLE in European Americans, Asians and Hispanics at p<5×10(-8) with consistent association in subjects with African ancestry. Of these, six SNPs located in the TMEM187-IRAK1-MECP2 region captured the underlying causal variant(s) residing in a common risk haplotype shared by all four ancestral groups. Among them, rs1059702 best explained the Xq28 association signals in conditional testings and exhibited the strongest p value in transancestral meta-analysis (p(meta )= 1.3×10(-27), OR=1.43), and thus was considered to be the most likely causal variant. The risk allele of rs1059702 results in the amino acid substitution S196F in IRAK1 and had previously been shown to increase NF-κB activity in vitro. We also found that the homozygous risk genotype of rs1059702 was associated with lower mRNA levels of MECP2, but not IRAK1, in SLE patients (p=0.0012) and healthy controls (p=0.0064).
CONCLUSIONS: These data suggest contributions of both IRAK1 and MECP2 to SLE susceptibility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904263      PMCID: PMC3567234          DOI: 10.1136/annrheumdis-2012-201851

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  40 in total

1.  Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation.

Authors:  M C Lorincz; D Schübeler; M Groudine
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  Control of confounding of genetic associations in stratified populations.

Authors:  Clive J Hoggart; Eteban J Parra; Mark D Shriver; Carolina Bonilla; Rick A Kittles; David G Clayton; Paul M McKeigue
Journal:  Am J Hum Genet       Date:  2003-06       Impact factor: 11.025

3.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

4.  Design and analysis of admixture mapping studies.

Authors:  C J Hoggart; M D Shriver; R A Kittles; D G Clayton; P M McKeigue
Journal:  Am J Hum Genet       Date:  2004-04-14       Impact factor: 11.025

Review 5.  Prospects for admixture mapping of complex traits.

Authors:  Paul M McKeigue
Journal:  Am J Hum Genet       Date:  2004-11-11       Impact factor: 11.025

6.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.

Authors:  X Nan; H H Ng; C A Johnson; C D Laherty; B M Turner; R N Eisenman; A Bird
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

7.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

8.  Identification of a domain conferring nucleotide binding to the N-acetyl-d-glucosamine 2-epimerase (Renin binding protein).

Authors:  Saori Takahashi; Hironobu Ogasawara; Keitaro Takahashi; Kazuyuki Hori; Kyuichi Saito; Katsumi Mori
Journal:  J Biochem       Date:  2002-04       Impact factor: 3.387

9.  Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis.

Authors:  John Arcaroli; Eliezer Silva; James P Maloney; Qianbin He; Daiva Svetkauskaite; James R Murphy; Edward Abraham
Journal:  Am J Respir Crit Care Med       Date:  2006-03-09       Impact factor: 21.405

Review 10.  The IL-1 family and inflammatory diseases.

Authors:  C A Dinarello
Journal:  Clin Exp Rheumatol       Date:  2002 Sep-Oct       Impact factor: 4.473

View more
  49 in total

1.  Methyl-CpG-Binding Protein 2 (MECP2) Polymorphism in Iranian Patients with Systemic Lupus Erythematosus.

Authors:  Samira Alesaeidi; Jafar Karami; Mahdi Mahmoudi; Mahmoud Akbarian; Shiva Poursani; Azadeh Amirzadeh; Nazgol-Sadat Haddadi; Elahe Saffari; Ahmad Reza Jamshidi
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 2.  Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies.

Authors:  Maria Teruel; Amr H Sawalha
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

Review 3.  Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Chandra Mohan; Chaim Putterman
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

4.  Genetics of the type I interferon pathway in systemic lupus erythematosus.

Authors:  Yogita Ghodke-Puranik; Timothy B Niewold
Journal:  Int J Clin Rheumtol       Date:  2013-12-01

Review 5.  When the balance is broken: X-linked gene dosage from two X chromosomes and female-biased autoimmunity.

Authors:  Camille M Syrett; Montserrat C Anguera
Journal:  J Leukoc Biol       Date:  2019-05-24       Impact factor: 4.962

Review 6.  Updates in Lupus Genetics.

Authors:  Yun Deng; Betty P Tsao
Journal:  Curr Rheumatol Rep       Date:  2017-10-05       Impact factor: 4.592

7.  Directional X Chromosome Skewing of White Blood Cells from Subjects with Heterozygous Mosaicism for the Variant IRAK1 Haplotype.

Authors:  Patrick Morcillo; Yong Qin; Geber Peña; Anne C Mosenthal; David H Livingston; Zoltan Spolarics
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 8.  Genetics of Lupus Nephritis: Clinical Implications.

Authors:  Melissa E Munroe; Judith A James
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

9.  New insight on the Xq28 association with systemic sclerosis.

Authors:  F David Carmona; M Carmen Cénit; Lina-Marcela Diaz-Gallo; Jasper C A Broen; Carmen P Simeón; Patricia E Carreira; José-Luis Callejas-Rubio; Vicente Fonollosa; Francisco J López-Longo; Miguel A González-Gay; Nicolas Hunzelmann; Gabriela Riemekasten; Torsten Witte; Alexander Kreuter; Jörg H W Distler; Rajan Madhok; Paul Shiels; Jacob M van Laar; Annemie J Schuerwegh; Madelon C Vonk; Alexandre E Voskuyl; Carmen Fonseca; Christopher P Denton; Ariane Herrick; Jane Worthington; Frank C Arnett; Filemon K Tan; Shervin Assassi; Timothy R D J Radstake; Maureen D Mayes; Javier Martín
Journal:  Ann Rheum Dis       Date:  2013-02-26       Impact factor: 19.103

10.  Overexpression of methyl-CpG-binding protein 2 and autoimmunity: evidence from MECP2 duplication syndrome, lupus, MECP2 transgenic and Mecp2 deficient mice.

Authors:  A H Sawalha
Journal:  Lupus       Date:  2013-07-16       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.